Skip to Content
Merck
All Photos(1)

Key Documents

PZ0394

Sigma-Aldrich

PF-05212377 succinate

≥98% (HPLC)

Synonym(s):

2-Methyl-1-(phenylsulfonyl)-4-piperazin-1-yl-1H-benzimidazole, succinate salt, PF 05212377 succinate, PF 5212377 succinate, PF-5212377 succinate, PF05212377 succinate, PF5212377 succinate, SAM-760 succinate, WYE-103760 succinate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C18H20N4O2S · xC4H6O4
Molecular Weight:
356.44 (free base basis)
UNSPSC Code:
12352202
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

room temp

Biochem/physiol Actions

PF-05212377 (SAM-760; WYE-103760) is an orally available, high-affinity, selective 5-hydroxytryptamine (5-HT; serotonin) receptor 5-HT6 antagonist (Ki/IC50 = 0.53/1.06 nM against 3 nM [3H]-LSD for binding human 5-HT6). PF-05212377 modulates glutamate and acetylcholine release in the cerebral cortex and hippocampus in rodents with in vivo pro-cognitive efficacy.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Terence Fullerton et al.
Alzheimer's research & therapy, 10(1), 38-38 (2018-04-07)
Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer's disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in humans at a dose of 30 mg. This was
Aarti Sawant-Basak et al.
Drug metabolism and disposition: the biological fate of chemicals, 46(7), 934-942 (2018-04-27)
SAM-760 [(2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole)], a 5HT6 antagonist, was investigated in humans for the treatment of Alzheimer's disease. In liver microsomes and recombinant cytochrome P450 (P450) isozymes, SAM-760 was predominantly metabolized by CYP3A (∼85%). Based on these observations and an expectation of a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service